OverviewSuggest Edit

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of innovative drugs to treat inflammatory conditions. There platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of novel mechanism of action therapies to safely and effectively treat inflammatory diseases.

TypePublic
Founded2008
HQCambridge, US
Websitecatabasis.com
Employee Ratings5

Latest Updates

Employees (est.) (Feb 2019)36
Revenue (FY, 2017)$500 K
Share Price (Feb 2019)$4.4 (-3%)

Key People/Management at Catabasis Pharmaceuticals

Jill C. Milne

Jill C. Milne

Ph.D. Co-Founder and Chief Executive Officer
Deirdre A. Cunnane

Deirdre A. Cunnane

Chief Legal Officer
Joanne M. Donovan

Joanne M. Donovan

Chief Medical Officer and Senior Vice President, Clinical Development
Andrew Nichols

Andrew Nichols

Ph.D. Chief Scientific Officer
Angelika Fretzen

Angelika Fretzen

Ph.D. Senior Vice President, Product Development
Joe Johnston

Joe Johnston

Vice President, Regulatory Affairs
Show more

Catabasis Pharmaceuticals Office Locations

Catabasis Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
1 Kendall Square B14202
Show all (1)
Report incorrect company information

Catabasis Pharmaceuticals Financials and Metrics

Catabasis Pharmaceuticals Revenue

Catabasis Pharmaceuticals's revenue was reported to be $500 k in FY, 2017
USD

Net income (FY, 2018)

(25.9m)

EBIT (FY, 2018)

(26.4m)

Market capitalization (8-Feb-2019)

309.0k

Closing stock price (8-Feb-2019)

4.4

Cash (31-Dec-2018)

15.3m
Catabasis Pharmaceuticals's current market capitalization is $309 k.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

500.0k

General and administrative expense

8.6m10.1m8.9m9.3m

R&D expense

23.0m25.5m18.7m17.0m

Operating expense total

31.7m35.6m27.6m26.4m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

250.0k

General and administrative expense

2.8m2.6m2.3m2.4m2.4m2.4m2.4m2.4m

R&D expense

6.4m6.8m5.9m5.4m4.5m4.8m5.2m4.2m

Operating expense total

9.2m9.4m8.3m7.8m6.9m7.2m7.6m6.6m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

62.8m23.6m16.4m15.3m

Inventories

804.0k1.0m

Current Assets

63.6m39.5m17.5m38.9m

PP&E

504.0k568.0k321.0k56.0k
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

81.5m72.7m23.8m24.3m26.5m31.8m29.4m21.7m17.0m49.9m

Current Assets

82.1m73.3m53.4m43.7m48.3m32.8m30.3m22.8m17.9m50.7m

PP&E

230.0k216.0k770.0k718.0k641.0k494.0k442.0k388.0k258.0k51.0k

Total Assets

82.5m73.7m54.3m44.6m48.9m33.4m30.8m23.3m18.3m50.8m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(32.6m)(36.1m)(27.4m)(25.9m)

Depreciation and Amortization

202.0k395.0k304.0k119.0k

Inventories

(450.0k)(229.0k)

Accounts Payable

196.0k77.0k(632.0k)662.0k
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(9.4m)(18.9m)(27.3m)(7.9m)(14.8m)(21.9m)(7.7m)(14.1m)

Depreciation and Amortization

195.0k300.0k88.0k165.0k237.0k62.0k105.0k

Accounts Payable

2.5m1.8m1.6m210.0k178.0k(468.0k)650.0k(203.0k)342.0k(402.0k)

Cash From Operating Activities

(18.0m)(24.9m)(8.1m)(13.8m)(21.2m)(6.8m)(12.4m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Catabasis Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Catabasis Pharmaceuticals News and Updates

Duchenne Muscular Dystrophy - Pipeline Review, H2 including key players Capricor Therapeutics , Catabasis Pharmaceuticals

A new independent 279 page research with title 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2018' guarantees you will remain better informed than your competition. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

Catabasis Pharmaceuticals Blogs

Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14

Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14 Content Import Thu, 02/28/2019 - 08:01 Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporat…

Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy Content Import Tue, 02/19/2019 - 08:05 Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne …

Joanne Beck

Joanne Beck Justin.Howard@… Thu, 02/14/2019 - 08:11 Member of the Science and Technology Committee Joanne Beck Executive Vice Present, Global Pharmaceutical Development and Operations, Celgene Joanne T. Beck, Ph.D. has served as a member of our Board of Directors …

Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors

Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors Content Import Thu, 02/14/2019 - 08:04 Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors February 14, 2019 at 8:00 AM EST This release is a backfill from a Ne…

Catabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public Offering

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 6, 2019-- Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of an aggregate of 4,000,000 units at a

Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2019-- Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it intends to offer its securities in an underwritten public offering.
Show more

Catabasis Pharmaceuticals Frequently Asked Questions

  • When was Catabasis Pharmaceuticals founded?

    Catabasis Pharmaceuticals was founded in 2008.

  • Who are Catabasis Pharmaceuticals key executives?

    Catabasis Pharmaceuticals's key executives are Jill C. Milne, Deirdre A. Cunnane and Joanne M. Donovan.

  • How many employees does Catabasis Pharmaceuticals have?

    Catabasis Pharmaceuticals has 36 employees.

  • Who are Catabasis Pharmaceuticals competitors?

    Competitors of Catabasis Pharmaceuticals include Vitality Biopharma, Opiant Pharmaceuticals and Mylan.

  • Where is Catabasis Pharmaceuticals headquarters?

    Catabasis Pharmaceuticals headquarters is located at 1 Kendall Square B14202, Cambridge.

  • Where are Catabasis Pharmaceuticals offices?

    Catabasis Pharmaceuticals has an office in Cambridge.

  • How many offices does Catabasis Pharmaceuticals have?

    Catabasis Pharmaceuticals has 1 office.